osteoporosis prof. dr. Ülkü akarırmak. metabolic bone diseases osteosclerosis osteolysis...
TRANSCRIPT
Metabolic Bone Diseases
Osteosclerosis
Osteolysis
Osteoporosis is the most common metabolic bone disease
Definition of Osteoporosis
A systemic skeletal disease
- characterized by low bone mass - microarchitectural deterioration of bone tissue
- with a consequent increase in bone fragility and susceptibility to fracture
Bone Turnover
- Osteoclasts - Bone resorption
- Osteoblasts - Bone formation
- Osteocytes
Formation=Resorption
Bone Metabolism
Local factors: Growth factors
3 Systemic hormones: - Parathormone - Vitamin D - Calcitonin
3 Involved systems: - Bone - Intestines - Renal
Risk Factors for Osteoporosis
Modifiable Inadequate exercise Inadequate nutrition
- calcium - vitamin D
- balanced diet Medications
- glucocorticoids - excess thyroid - etc.
Smoking Excessive alcohol intake
Clinical Picture
The traditional picture of an individual with osteoporosis:
An elderly woman with a curved back and stooped posture, a woman who has lost height and who appears small and frail
Major Osteoporotic Fractures
Type Colles Vertebral Hip
Typical age 55 65 75
Female:male ratio 4:1 3:1 2:1
Pathogenesis of Osteoporotic Fracture
LOW PEAK POSTMENOPAUSAL AGE-RELATEDBONE MASS BONE LOSS BONE LOSS
Low Bone Mass Other risk factors
Nonskeletal FRACTURE Poor bone quality
factors Increased risk of falls
Clinical Results of Osteoporotic Fractures
Pain Reduction in physical activity Deformity Muscle weakness Social isolation Loss of independence Increased mortality
Evaluation of Osteoporosis
Identify risk factors for OP
Identify contributing factors Medical history: Secondary OP
Physical examination
DXA
X-ray
Laboratory Evaluation
Radiographic Evaluation
0 Normal 1 End plate deformity 2 Fish vertebrae 3 End plate fracture 4 Wedge vertebrae 5 Compression
fracture
Diagnosis of Osteoporosis
Osteodensitometry DXA
DXA = Dual X- ray Absorptiometry
Bone Mineral Density BMD
Indications for Bone Densitometry
Female patients > 65 years Patients with osteoporosis risk factors Vertebral abnormalities and/or osteopenia on x-rays Long – term glucocorticoid therapy Primary hyperparathyroidism or other diseases with
high risk of OP Patients being treated for OP, to monitor changes in
bone mass
Diagnosis Based on BMD (WHO)
BMD T-score
Normal 0 - (-1)SD
Osteopenia (-1) - (-2.5)SD
Osteoporosis <(-2.5)SD
Established OP ‘’ + fracture
Recommendations Based on BMD
BMD Risk of Fx Action
Normal Very low Prevention
Osteopenia Low Prevention
OP High<(-2.5)SD Treatment
Establ OP Very high Treatment
Osteodensitometry is the most important method for diagnosis
Fracture risk may be assessed Low BMD is associated with increased fracture
risk
Laboratory Tests
- Routine Biochemistry Serum calcium Phosphorus Alkaline phosphatase Creatinine Total protein,albumin,and globulin 25(OH)Vitamin D
- Complete blood count
- Sedimantation rate
- Biochemical markers of bone turnover
Osteoporosis is a….
Preventable Treatable disease
Recommendations 1. Nutrition 2. Activity 3. Vitamin D
Approaches for Management of Osteoporosis: Pharmac&Nonpharmacologic
Prevent fractures - Medical therapy
- Prevention of falls
Improve physical function
Improve quality of life
Osteoclast
Inhibition of Resorption
Osteoblast
Stimulation of Formation
Therapeutic Agents Used in Osteoporosis
Inhibitors of Bone Resorption
Calcium HT: Estrogens +/- progestogens SERMs Bisphosphonates Alendronate Zoledronate Risedronate Ibandronate Calcitonin
Calcium – Vitamin D
Calcium - Adults : 1000 mg
Increased: Over 65 years, after menopause,
pregnancy, stilling Vitamin D :
Adults : 400-800 IU
Over 70 years: >800 IU
HRT: Estrogen
Reduces the rate of bone loss Reduces fracture risk in
postmenopausal women
Adverse effects; WHI
Limited time
Calcitonin
Reduces bone loss in postmenopausal women- bone quality
Effective on spinal fractures
Opt.dose: 200 IU/daily nasal spray
High tolerability
Bisphosphonates: Gold Standard Indication: PMO
Male OP
GIO
Decrease fracture incidenceALN: 70mg/w ZOL: 5mgIV/yearly infusion
RIS: 35mg/w-75/mo IBN:150mg/mo - 3mg 3mo inf
Contraindication: Oesaphageal irritation
Strategies for Reducing Falls and Fractures
- Maintain physical activity
- Provide a safe home environment
- Balance training
- Ambulatory support when appropriate
- Avoid sedative medications
- Minimize other contributing medical problems
- Hip pads in the frail elderly